N-propionyl-4-S-cysteaminylphenol induces apoptosis in B16F1 cells and mediates tumor-specific T-cell immune responses in a mouse melanoma model

Journal of Dermatological Science

Volumn 67, Issue 1, 2012, Pages 51-60

  Ishii Osai, Yasue ^a   Yamashita, Toshiharu ^a   Tamura, Yasuaki ^a   Sato, Noriyuki ^a   Ito, Akira ^b   Honda, Hiroyuki ^c   Wakamatsu, Kazumasa ^d   Ito, Shosuke ^d   Nakayama, Eiichi ^e   Okura, Masae ^a   Jimbow, Kowichi ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY   (Japan)

^d FUJITA HEALTH UNIVERSITY   (Japan)

^e KAWASAKI UNIVERSITY OF MEDICAL WELFARE   (Japan)

Author keywords

Apoptosis; Melanogenesis; N propionyl 4 S cysteaminylphenol; Reactive oxygen species; Tumor suppression; Tyrosinase related protein

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; CASPASE 3; CD4 ANTIBODY; CD8 ANTIBODY; CELL DNA; N PROPIONYL 2 S CYSTEAMINYLPHENOL; N PROPIONYL 4 S CYSTEAMINYLPHENOL; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL COUNT; CELL GROWTH; CELL SPECIFICITY; CELL STRAIN; CELL STRAIN B16F1; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOASSAY; LYMPH NODE CELL; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIMARY MELANOMA; PRIMARY TUMOR; PRIORITY JOURNAL; SECONDARY MELANOMA; SPLEEN CELL;

ANIMALS; ANTIBODIES; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; CYSTAMINE; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNITY, CELLULAR; INTRAMOLECULAR OXIDOREDUCTASES; MELANINS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NIH 3T3 CELLS; PHENOLS; REACTIVE OXYGEN SPECIES; TIME FACTORS; TUMOR BURDEN;

EID: 84862178042     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2012.04.009     Document Type: Article

References (38)

1. Ishihara K., Saida T., Otsuka F., Yamazaki N. Prognosis and Statistical Investigation Committee of the Japanese Skin Cancer Society. Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update. Int J Clin Oncol 2008, 13:33-41.
2. Balch C.M., Gershenwald J.E., Soong S.J., Thompson J.F., Atkins M.B., Byrd D.R., et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27:6199-6206.
3. Rad H.H., Yamashita T., Jin H.Y., Hirosaki K., Wakamatsu K., Ito S., et al. Tyrosinase-related proteins suppress tyrosinase-mediated cell death of melanocytes and melanoma cells. Exp Cell Res 2004, 298:317-328.
4. Jimbow K., Miura S., Ito Y., Kasuga T., Ito S. Utilization of melanin precursors for experimental chemotherapy of malignant melanoma. Jpn J Cancer Chemother 1984, 11:2125-2132.
5. Ito S., Kato T., Ishikawa K., Kasuga T., Jimbow K. Mechanism of selective toxicity of 4-S-cysteinylphenol and 4-S-cysteaminylphenol to melanocytes. Biochem Pharmacol 1987, 36:2007-2011.
6. Pankovich J.M., Jimbow K., Ito S. 4-S-cysteaminylphenol and its analogues as substrates or tyrosinase and monoamine oxide. Pigment Cell Res 1990, 3:146-149.
7. Miura T., Jimbow K., Ito S. The in vivo antimelanoma effect of 4-S-cysteaminylphenol and its N-acetyl derivative. Int J Cancer 1990, 46:931-934.
8. Alena F., Iwashita T., Gili A., Jimbow K. Selective in vivo accumulation of N-acetyl-4-cysteaminylphenol in B16F10 murine melanoma effect by combination of buthionine sulfoximine. Cancer Res 1994, 54:2661-2666.
9. Tandon M., Thomas P.D., Shokravi M., Singh S., Samra S., Chang D., et al. Synthesis and antitumor effect of the melanogenesis-based antimelanoma agent N-propionyl-4-S-cysteaminylphenol. Biochem Pharmacol 1998, 55:2023-2029.
10. Minamitsuji Y., Toyofuku K., Sugiyama S., Yamada K., Jimbow K. Sulfur containing tyrosine analogs can cause selective melanocytotoxicity involving tyrosinase-mediated apoptosis. J Invest Dermatol Symp Proc 1999, 4:130-136.
11. Thomas P.D., Kishi H., Cao H., Ota M., Yamashita T., Singh S., et al. Selective incorporation and specific cytocidal effect as the cellular basis for the antimelanoma action of sulphur containing tyrosine analogs. J Invest Dermatol 1999, 113:928-934.
12. Sato M., Yamashita T., Okura M., Osai Y., Sato A., Takada T., et al. N-propionyl-cysteaminylphenol-magnetite conjugate (NPrCAP/M) is a nanoparticle for the targeted growth suppression of melanoma cells. J Invest Dermatol 2009, 129:2233-2241.
13. Eikawa S., Ohue Y., Kitaoka K., Aji T., Uenaka A., Oka M., et al. Enrichment of Foxp3+ CD4 regulatory T cells in migrated T cells to IL-6- and IL-8-expressing tumors through predominant induction of CXCR1 by IL-6. J Immunol 2010, 185:6734-6740.
14. Miura S., Ueda T., Jimbow K., Ito S., Fujita K. Synthesis of cysteinylphenol, cysteaminylphenol, and related compounds, and in vivo evaluation of antimelanoma effect. Arch Dermatol Res 1987, 279:219-225.
15. L. Cancer Res 1996, 56:2161-2166.
16. Rotman A., Daly J.W., Creveling C.R. Oxygen-dependent reaction of 6-hydroxydopamine,5,6-dihydroxytryptamine and related compounds with proteins in vivo: a model for cytotoxicity. Mol Pharmacol 1976, 12:887-899.
17. Ito S., Inoue S., Fujita K. The mechanism of toxicity of 5-S-cysteinyldopa to tumour cells. Hydrogen peroxide as a mediator of cytotoxicity. Biochem Pharmacol 1983, 32:2079-2081.
18. Yamada K., Jimbow K., Engelhardt R., Ito S. Selective cytotoxicity of a phenolic melanin precursor, 4-S-cysteaminylphenol, on in vitro melanoma cells. Biochem Pharmacol 1989, 38:2217-2221.
19. Solano F., Briganti S., Picardo M., Ghanem G. Hypopigmenting agents: an updated review on biological, chemical and clinical aspects. Pigment Cell Res 2006, 19:550-571.
20. Ito Y., Jimbow K., Ito S. Depigmentation of black guinea pig skin by topical application of cysteaminylphenol, cysteinylphenol, and related compounds. J Invest Dermatol 1987, 88:77-82.
21. Ito Y., Jimbow K. Selective cytotoxicity of 4-S-cysteaminylphenol on follicular melanocytes of the black mouse: rational basis for its application to melanoma chemotherapy. Cancer Res 1987, 47:3278-3286.
22. Jimbow K., Iwashina T., Alena F., Yamada K., Pankovich J., Umemura T. Exploitation of pigment biosynthesis pathway as a selective chemotherapeutic approach for malignant melanoma. J Invest Dermatol 1993, 100:S231-S238.
23. Wick M.M. Levodopa and dopamine analogs as DNA polymerase inhibition and antitumor agents in human melanoma. Cancer Res 1980, 40:1414-1418.
24. Yamada I., Seki S., Ito S., Matsubara O., Kasuga T. The killing effect of 4-S-cysteaminylphenol, a newly synthesized melanin precursor, on B16 melanoma cell lines. Br J Cancer 1991, 63:187-190.
25. Hasegawa K., Ito S., Inoue S., Wakamatsu K., Ozeki H., Ishiguro I. Dihydroxy-1,4-benzothiazine-6,7-dione, the ultimate toxic metabolite of 4-S-cysteaminylphenol and 4-S-cysteaminylcatechol. Biochem Pharmacol 1997, 53:1435-1444.
26. Denning T.L., Takaishi H., Crowe S.E., Boldogh I., Jevnikar A., Ernst P.B. Oxidative stress induces the expression of Fas and Fas ligand and apoptosis in murine intestinal epithelial cells. Free Radic Biol Med 2002, 33:1641-1650.
27. Circu M.L., Aw T.Y. Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med 2010, 48:749-762.
28. Shellman Y.G., Howe W.R., Miller L.A., Goldstein N.B., Pacheco T.R., Mahajan R.L., et al. Hyperthermia induces endoplasmic reticulum-mediated apoptosis in melanoma and non-melanoma skin cancer cells. J Invest Dermatol 2008, 128:949-956.
29. 2. Mol Cell Biol 2004, 24:36-45.
30. 2-induced oxidative stress via the Nrf2-ARE pathway. J Invest Dermatol 2011, 131:1420-1427.
31. Ito A., Tanaka K., Kondo K., Shinkai M., Honda H., Matsumoto K., et al. Tumor regression by combined immunotherapy and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma. Cancer Sci 2003, 94:308-313.
32. Suzuki M., Shinkai M., Honda H., Kobayashi T. Anticancer effect and immune induction by hyperthermia of malignant melanoma using magnetite cationic liposomes. Melanoma Res 2003, 13:129-135.
33. Sato A., Tamura Y., Sato N., Yamashita T., Takada T., Sato M., et al. Melanoma-targeted chemo-thermo-immuno (CTI)-therapy using N-propionyl-4-S-cysteaminylphenol-magnetite nanoparticles elicits CTL response via heat shock protein-peptide complex release. Cancer Sci 2010, 101:1939-1946.
34. Bronte V., Apolloni E., Ronca R., Zamboni P., Overwijk W.W., Surman D.R., et al. Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. Cancer Res 2000, 60:253-258.
35. Mendiratta S.K., Thai G., Eslahi N.K., Thull N.M., Matar M., Bronte V., et al. Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp100 and TRP-2. Cancer Res 2001, 61:859-863.
36. Ji Q., Gondek D., Hurwitz A.A. Provision of granulocyte-macrophage colony-stimulating factor converts an autoimmune response to a self-antigen into an antitumor response. J Immunol 2005, 175:1456-1463.
37. Westerhof W., d'Ischia M. Vitiligo puzzle: the pieces fall in place. Pigment Cell Res 2007, 20:345-359.
38. Westerhof W., Manini P., Napolitano A., d'Ischia M. The haptenation theory of vitiligo and melanoma rejection: a close-up. Exp Dermatol 2011, 20:92-96.